All In Biotech

Free tool

FAERS Monitor: Glycophos

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220381 or its brand name (Glycophos, Sodium Glycerophosphate). Reports on generic versions are filed under their own applications.

Reports

364

Serious

358

98% of reports

Hospitalization

213

Death reported

52

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malaise47
  • pyrexia43
  • vomiting30
  • nausea29
  • chills26
  • dyspnoea26
  • body temperature increased19
  • death18
  • device related infection17
  • tremor17
  • diarrhoea16
  • abdominal pain15
  • product preparation error14
  • chest pain12
  • fatigue12

Reports by year received

View as table
YearReports
20122
201419
20157
201622
201723
201872
201940
202013
202119
202222
202332
202425
202513
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,795 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device related infectionSignal1763.940.2990
body temperature increasedSignal1953.934.8934
product preparation errorSignal1439.423.6486
chillsSignal2612.88.8273
pyrexiaSignal437.25.4226
malaiseSignal476.24.7204
tremorSignal175.93.765
chest painSignal123.72.122
abdominal painSignal153.72.328
vomitingSignal303.72.657
dyspnoeaSignal262.71.826
nauseaSignal292.11.517
diarrhoea161.40.92
death181.20.80
fatigue120.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.